Source comparison
CJC-1295 No DAC Ipamorelin for Pulsatile GH Research: Dosing Comparison
CJC-1295 No DAC 100–200 mcg per administration 30 minutes 60–90 minutes post-injection GHRH receptor (cAMP-mediated somatotroph stimulation) Shortest-acting GHRH analog; replicates endogenous clearance kinetics required for true pulsatile protocols Ipamorelin
This comparison does not assign a generated winner or score.
- CJC-1295 No DAC
- 100–200 mcg per administration
- 30 minutes
- 60–90 minutes post-injection
- GHRH receptor (cAMP-mediated somatotroph stimulation)
- Shortest-acting GHRH analog; replicates endogenous clearance kinetics required for true pulsatile protocols
- Ipamorelin
- 200–300 mcg per administration
- 2 hours
- 30–45 minutes post-injection
- Ghrelin receptor GHS-R1a (calcium mobilization pathway)
- Selective ghrelin mimetic with no cortisol or prolactin cross-reactivity; ideal for isolating GH-specific effects
- CJC-1295 with DAC
- 1000–2000 mcg weekly
- 6–8 days
- Continuous low-level elevation
- GHRH receptor (extended binding via DAC modification)
- Produces tonic GH secretion unsuitable for pulsatile research; useful for sustained-release pharmacology studies
- GHRP-6
- 20–30 minutes
- 20–30 minutes post-injection
- Ghrelin receptor (non-selective; activates cortisol/prolactin pathways)
- Older secretagogue with broader receptor activation; confounds metabolic data with stress hormone interference
- CJC-1295 No DAC and Ipamorelin together produce the highest-fidelity replication of endogenous pulsatile GH release. Short clearance windows, synergistic receptor pathways, and no hormonal cross-talk. DAC-modified analogs eliminate pulsatility entirely. GHRP-6 introduces cortisol confounds. For research isolating GH-specific metabolic or anabolic effects, No DAC plus Ipamorelin is the standard.